Q3-FY26 · Badri
3.6% increase in revenue resulted in 8 plus percentage increase in gross margins plus the 12% increase in EBITDA and almost 38% increase in PAT. The multiple multiplier effect is very very visible in the financials.
STAR / language trends
Read confidence between the lines.
Strides Pharma Science · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q3-FY26 · Badri
The growth will be led by many levers which are all part of this as far as the US is concerned we have got number of dominant products the control substances should pan out quite well for us in the near term.
Q3-FY26 · Badri
Our endeavor is to get a very diversified company and if you see the gap between the non US and the XUS and the US it's come down to almost about 50 crore the difference in the revenue for the quarter.